The perfect storm approaches...a drug that has been test...

First 43 Last

Share
Profile

Follow
Darksky

142 Posts.

33

27/03/21

17:26

Post #: 52086364
Share

Originally posted by Darksky: ↑

You never go broke taking a profit, I can't remember who gave me that advice but it's good,

But back to the prospect of having a substantial short position in a stock with tremendous potential IMHO.

What kind of a gap up in price might we expect if the IND for Zilusol is approved?!
I have absolutely no idea. But we are talking about a drug that has been test successfully (on evidence provided here) with over 600 SAS patients, has a long safety record in use with animals, has already caught the attention of pharmaceutical companies (again evidence here) and has a very significant market for it's use.

So, say I was running a managed fund I was short 10 million shares and had the financial capacity to run the price up and down and shake the odd loose holder out from time to time to help cover some of my position and make and book profits month by month along the way and meet my trading profit targets for managerment. What would happen if PAR receives early approval for the IND? would the share price gap up at open (remembering the FDA is in America and their announcement may occur in US time) by $2.50 to $3.00, I really don't know, but if you're short 10 million shares that's a $25 to $30 million loss. And then, what if that announcement was quickly followed by a significant deal with big pharma? Again I have absolutely no idea what that would do to the price. But what if it was an additional $5 gap up that's a potential combined loss of $75 to $80 million. Ouch!!!, and if it's an additional $10 gap up that's potentially a total loss of $125 to $130 million on the one position. Now if I was an agressive fund manager without a position in PAR and I could see the large short position and understood all the evidence about the drug, would I/they see that as an apportunity to put a short squeeze into play. I really don't know, I'm not a fund manager.But If that did occur (depending on the size of the fund) that loss could put their fund into the bottom quartile relative to their peers for quite a while. IMHO DYOR. Anyway, lets just say that a squeeze might just put a STOP to their GAME.
imho dyor

Expand

The perfect storm approaches...

a drug that has been test successfully (based on evidence provided here) with over 600 SAS patients, has a long safety record in use with animals, has already caught the attention of pharmaceutical companies (again evidence here) and has a very significant market for it's use...

AND COMPETITION HAS JUST BEEN ELIMINATED!!!

PAR Price at posting: $2.65 Sentiment: Buy Disclosure: Held
19 Upvote

0 Great analysis

Reply

Top Stories

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

There are more pages in this discussion • 9 more messages in this thread...

First 43 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 26.5¢		Change -0.020(7.02%)		Mkt cap ! $92.69M

Open	High	Low	Value	Volume
29.0¢	29.0¢	26.0¢	$229.3K	833.1K

Buyers (Bids)

No.	Vol.	Price($)
9	89111	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
27.0¢	25136	1

View Market Depth

No.	Vol.	Price($)
9	89111	0.260
3	53215	0.255
5	133500	0.250
5	72763	0.245
6	87200	0.240

Price($)	Vol.	No.
0.270	25136	1
0.285	10000	1
0.290	14580	3
0.300	18807	4
0.305	50000	1

Last trade - 16.10pm 25/07/2024 (20 minute delay)

PAR (ASX) Chart

The perfect storm approaches...a drug that has been test...

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The perfect storm approaches...a drug that has been test...

Top Stories

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News